GLW
42
-3
SE
72
-3
PHM
47
-8
MCO
64
-4
DHI
35
-6
LYB
23
-4
PFE
35
-2
AXP
57
-3
XRAY
16
-4
MCHP
37
-5
HBI
56
-3
SCHW
62
-5
GD
49
-3
RCL
62
-7
PEP
53
-3
NWL
41
-2
BMY
50
5
FAST
42
-4
ROST
49
-3
CMS
55
2
GLW
42
-3
SE
72
-3
PHM
47
-8
MCO
64
-4
DHI
35
-6
LYB
23
-4
PFE
35
-2
AXP
57
-3
XRAY
16
-4
MCHP
37
-5
HBI
56
-3
SCHW
62
-5
GD
49
-3
RCL
62
-7
PEP
53
-3
NWL
41
-2
BMY
50
5
FAST
42
-4
ROST
49
-3
CMS
55
2
Financhill
Back

BridgeBio Pharma 10K Form

Sell
39

BBIO
BridgeBio Pharma

Last Price:
$35.11
Seasonality Move:
1.07%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive BBIO News And Ratings

See the #1 stock for the next 7 days that we like better than BBIO

BBIO Financial Statistics

Sales & Book Value

Annual Sales: $221.9M
Cash Flow: $-198.6M
Price / Cash Flow: 0
Annual Sales: $-7.72
Price / Book: 0

Profitability

EPS (TTM): -2.85000
Net Income (TTM): $-535.8M
Gross Margin: $218M
Return on Equity: 0%
Return on Assets: -70.97%

BridgeBio Pharma Earnings Forecast

Key BridgeBio Pharma Financial Ratios

  • The Gross Profit Margin over the past 8 years for BBIO is 98.25%.
  • The Selling, General & Administrative Expenses for BBIO have been equal to 130.21% of Gross Profit Margin.
  • The Research & Development expenses have been 228.24% of Revenue.
  • The Net Earning history of BBIO is -241.44% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 2 years.

BridgeBio Pharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: BBIO
CUSIP: 10806X
Website: bridgebio.com

Debt

Debt-to-Equity Ratio: -1.17
Current Ratio: 4.67
Quick Ratio: 4.44

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

BBIO Technical Analysis vs Fundamental Analysis

Sell
39
BridgeBio Pharma (BBIO) is a Sell

Is BridgeBio Pharma a Buy or a Sell?

  • BridgeBio Pharma stock is rated a Sell
    The current BridgeBio Pharma [BBIO] share price is $35.11. The Score for BBIO is 39, which is 22% below its historic median score of 50, and infers higher risk than normal.